Cargando…

Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome

Direct-acting antivirals (DAA) have replaced interferon (IFN)-based therapies for hepatitis C virus. In this retrospective clinical study, we examined differences in histopathologic features in paired liver biopsies collected from the same patient before and after DAA and correlated these findings w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saldarriaga, Omar A., Dye, Bradley, Pham, Judy, Wanninger, Timothy G., Millian, Daniel, Kueht, Michael, Freiberg, Benjamin, Utay, Netanya, Stevenson, Heather L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282660/ https://www.ncbi.nlm.nih.gov/pubmed/34267267 http://dx.doi.org/10.1038/s41598-021-93881-7

Ejemplares similares

258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C
por: Millian, Daniel, et al.
Publicado: (2023)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Direct‐Acting Antiviral Treatment of Patients with Hepatitis C Resolves Serologic and Histopathologic Features of Autoimmune Hepatitis
por: Simoes, Camila C., et al.
Publicado: (2019)

Multispectral Imaging Enables Characterization of Intrahepatic Macrophages in Patients With Chronic Liver Disease
por: Saldarriaga, Omar A., et al.
Publicado: (2020)

Cutting-Edge Platforms for Analysis of Immune Cells in the Hepatic Microenvironment—Focus on Tumor-Associated Macrophages in Hepatocellular Carcinoma
por: Millian, Daniel E., et al.
Publicado: (2022)

Fibrogenic Gene Expression in Hepatic Stellate Cells Induced by HCV and HIV Replication in a Three Cell Co-Culture Model System
por: Akil, Abdellah, et al.
Publicado: (2019)

373 Identification of potential targets for immunotherapy in a cynomolgus macaque model of Ebola virus disease
por: Wanninger, Timothy, et al.
Publicado: (2023)

Macrophage infection, activation, and histopathological findings in ebolavirus infection
por: Wanninger, Timothy G., et al.
Publicado: (2022)

Interferons and HIV Infection: The Good, the Bad, and the Ugly
por: Utay, Netanya S., et al.
Publicado: (2016)

1048. Weight Gain after Initiation of Anti-Retroviral Therapy in Acute HIV-1
por: Kaur, Harmanpreet, et al.
Publicado: (2020)

Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy
por: Offor, Obiageli, et al.
Publicado: (2018)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid
por: Pham, Timothy T., et al.
Publicado: (2018)

Hepatitis C Virus in the Elderly in the Direct-Acting Antiviral Era: from Diagnosis to Cure
por: Mohammed Abdul, Mubeen Khan, et al.
Publicado: (2020)

Myocardial perfusion reserve in patients with chronic hepatitis C before and after direct‐acting antiviral treatment—a pilot study
por: Sølund, Christina, et al.
Publicado: (2022)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
por: Soriano, Vicente, et al.
Publicado: (2022)

The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals
por: Townshend-Bulson, Lisa, et al.
Publicado: (2021)

Potential use of serum‐derived bovine immunoglobulin/protein isolate for the management of COVID‐19
por: Utay, Netanya S., et al.
Publicado: (2021)

Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C
por: Tse, Chung Sang, et al.
Publicado: (2020)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Primary Hepatic Mesothelial Cyst: A Rare Entity to Be Considered in the Differential Diagnosis of Neonatal Cystic Lesions
por: Gosnell, Joseph M, et al.
Publicado: (2022)

Acute HIV infection (AHI): Trained Service Linkage Workers and fourth-generation Assay Significantly Shorten Time to Antiretroviral Therapy Initiation.
por: Smith, Daniel, et al.
Publicado: (2017)

Towards supporting greater and lower cost access to direct acting antiviral treatment for hepatitis C for all patients
por: Al-Busafi, Said A., et al.
Publicado: (2017)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
por: Wang, Yadong, et al.
Publicado: (2022)

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM
por: Millard, James Daniel, et al.
Publicado: (2016)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
por: Hill, Andrew, et al.
Publicado: (2018)

Hepatitis C virus infection in children in the era of direct-acting antiviral
por: Pawlowska, Malgorzata, et al.
Publicado: (2018)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19
por: Kumar, Pramod, et al.
Publicado: (2021)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
por: Zeng, Haiyan, et al.
Publicado: (2020)

Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
por: John, Jason J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uv94fu5dlkr3p3o43j29s7ju0a